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Abstract. A series of 53 organic chemicals belonging to the groups oforganic phos-
phates, sulfonyl derivatives and carbamates were screened for their activity against the
coagulation factors IIu (thrombin), VII., IX" and Xu. Relatively specific inhibitors for the
factors II", VII. and Xu were found.
Introduction
In the past decade, much progress has been made in the characteriza-
tion of the molecular processes underlying blood coagulation (table I). The
activation reactions occurring in the coagulation pathways are highly spe-
cific, limited proteolysis reactions; the activated coagulation factors with
the exception of factors V" and VIII. belong to the class of the serine pro-
teases. When comparing the amino acid sequences around the active-site
serine residues of the coagulation factors with those of the pancreatic
enzymes chymotrypsin, trypsin and elastase, it can be seen that a high
degree of sequence homology exists among these proteins [4]. Furthennore,
thrombin and factor Xu contain histidine and asparagin residues in posi-
tions corresponding with the active-site histidine and asparagin residues
present in trypsin and chymotrypsin. In the case of thrombin and factor Xu,
I This work has been described in full detail in the PhD thesis of the first author
(kyden University, 1976).
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Inhibition of Activated Clotting Factors
the amino acid sequence of the active-site-bearing chain shows about 40-
450/o sequence homology with trypsin. These data strongly suggest a close
analogy between the coagulation factors and the pancreatic enzymes with
respect o the activation of the zymogen and the catalytic mechanism of the
active enzyme. Most likely, the substrate-binding pocket of the coagulation
proteases will resemble that of trypsin because all coagulation proteases are
specific towards basic amino acids (table I).
The main differences between the coagulation factors and the digestive
enzymes are the presence ofa second protein chain in the coagulation fac-
tors not involved in the catalytic reaction per se and, perhaps as a conse-
quence ofthe occurrence ofthis additional protein part, the higher substrate
specificity of the coagulation factors.
Of course, the tertiary structure of the coagulation factors can only be
proven by crystallographic studies of these enzymes and their (natural) sub-
strates, but valuable information can be obtained from work with model
substrates. In these studies, small changes in the substrate structure can be
introduced, and the effects on the enzyme-substrate interaction brought
about by these small changes can give useful information about the sub-
strate-binding site and the catalytic site of the enzymes. The same holds true
for inhibitors.
The aim of the work presented here was to find specific inhibitors for
the different coagulation factors. The availability of such specific inhibitors
would be useful for the study of the mechanism of blood coagulation and for
the chemical determination of the coagulation factors. The stereochemistry
of the specific inhibitors could contribute to our knowledge of the structure
of the active site of the coagulation factors, and finally, the specific inhibi-
tors might possibly be used therapeutically. In the experiments described
here, the inhibitory capacity towards the activated coagulation factors was
checked for a series of organic compounds belonging to the organic phos-
phates, the sulfanyl derivatives and the carbamates. Other groups have used
the same approach, but the families of inhibitors investigated here have, to
our knowledge, not been screened before [13, 16, 30, 3l].
Materials and Methods
Isolation and Purification of the Factors IIo, VII", IX, and Xo lsee also 401
As starting material, a coagulation factor concentrate containing the factors II, VII,
IX, and X was prepared according to Swart [37]. The coagulation factor concentrate was
activated with thromboplastin and Ca2*; the activated coagulation factors were separated
J L I
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by chromatography on a Whatman DE 32 column. (For the factors IIn and VII. the best
results were obtained when the isolation was carried out at 4'C; for factor Xn the best
results were obtained when the isolation occurred at room temperature.) It was not possible
to obtain factor IXu by this procedure, presumably because the starting material did not
contain a sufficient amount of this factor. However, when the coagulation factor concen-
trate was activated with contact product, a factor IXu preparation could be obtained. This
preparation always contained factor XI" (from the contact product) and was only used in
preliminary experiments. It was also possible to isolate a factor VII. - IXu * Xu concentrate
from serum and to isolate the factors VII. and X" from this concentrate by chromatography
on Sephadex G-100.
No attempt was made to obtain preparations that contained clotting factors that could
be considered pure by the usual physicochemical criteria. Preparations that contained one
coagulation factor in excess and no or trace activities ofthe others were considered su{Ii-
ciently pure for our purposes. This is because the inhibitors are added in large molar excess
anyhow, and the tests employed are sufficiently specihc not to be influenced by trace
amounts of inhibited or uninhibited coagulation factors other than the one under investi-
gatlon.
C oagul at io n F actor Reagents
These reagents were prepared according lo Koller et al. [20] and Loeliger and Koller
[23] (factor II); according ro Borchgrevink et al. [] (factor V); according to Hemker et al.
[2] (factorsVII and X); according lo Denson [5] (factorVII/X reagent). The factorVIII
and factor IX reagents were obtained from a patient with a severe deficiency ofthe respec-
tive coagulation factor (< I 0/o activity) (440 ml blood collected in a siliconized glass vessel
containing 60 ml ACD solution; storage at -20'C). Factor XI reagent was obtained from
congenital factor XI deficient plasma.
Thromboplastin was prepared from human brain accordingto Owren and Aas 1321.
Contact product was prepared according lo Niewiarowski et al. 1291.
Determination of Coagulation Factors
For the estimation of the factors II, V, VII and X, one-stage estimations were carried
out as describedby van der Meer et al. 126l; the factors VIII and IX were estimated accord-
ing to Veltkamp et al. l42l; factor XI was estimated according lo Horowitz et al. I I 4].
Determination of the Activated Coagulation Factors
FactorII" was determined according to Hemker et al. [11]; factorVll" in the same
system as factorVll [26] but with phospholipids instead of thromboplastin: the fac-
tors VIII" and IX" in the same systems as used for factors VIII and IX [42] except that no
kaolin was added to the test system and the incubation time of sample and reagent prior to
recalcification was I min instead of 30 min; factor Xu was determined in a one-stage test
with a factorVII and X deficient reagent and phospholipid [26].
Inhibitors were the same as described by Meyers l27l and Meyers et al. [28].
I nhibition Experiments
The coagulation factor (concentration about l0-6-10-r mol/l) was incubaled with the
inhibitor (concentration about l0-2-10-+ mol/l) at pH 7 .4, 37 'C, in siliconized gJass or in
plastic during 30 min (the concentrations of the coagulation factors were: thrombin.
Inhibition of Activated Clotting Factors
12.5 NIH U/ml; factor VII", 0.4-{.6 U/ml; factor IX", 0.15-0.25 U/ml; factor X", 0.5-
0.75 U/ml; the final inhibitor concentration is given in tables II-V. If there was no or only a
slight inhibition after 30min, the enzymatic activity was tested again. after 1,2,3 or,
sometimes, 18 h.
All chemicals were p.a. grade from Merck.
Protein concentrations were determined by measurirS Ezson. in a Zeiss PM Q I I
spectrophotometer. It was assumed that for prothrombin and thrombin, I extinction unit
at 280 nm corresponds with 1.6 mg protein/ml |7,371and for all other protein mixtures
with I mg protein/ml [36].
For a number of compounds the nuclear magnetic resonance (NMR) spectra were
recorded in a Jeol PS 100 NMR apparatus; sweep time 250s, sweep width l,080Hz
(X0.01 ppm). The organic compounds were dissolved in CDCIr; with the compounds
No. l, 7, 13, and 30, a little deuterated aceton was added.
Results and Discussion
Within a series of related inhibitors that are all able to react with an
active-site serine residue, the actual course ofthe reaction is determined by
the stereochemistry of the enzyme around the aclive-site residue [21].
Therefore, it can be expected that the differences between the coagulation
factors will be reflected in their susceptibility towards related inhibitors
with varying chemical structure. As far as small substrates are considered,
this is the same phenomenon that accounts for substrate specificity. For this
reason, the interaction of series of serine esterase inhibitors with the fac-
tors II", VII., IXu, and Xa has been investigated.
The evaluation of the kinetic constants of the inhibition process was
based on the following general scheme for the reaction of serine proteases
with irreversible inhibitors.
J19
E + I
K + r k + l
E. I  -+ Eqn6;6;66 * P
with
For this situation the steady-state approximation yields
-ql#L = k.r ([E] [r] - Ki [E . r]) = o
, ,  k-r + h:
*' = 
L*,
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Fig. 1. Time course of the inhibition of thrombin by dinitrophenyl-benzyl-phosphate
in the followingconcentrations: o = blank; o= 0.08 mmol; * = 0.19 mmol;Q- 0.31 mmol;
* = 0.39 mmol.
Fig.2. The dependence of kuoo on the concentration of dinitrophenyl-benzyl-phos-
phate.
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If [EukJ stands for [E] + [E. I], the total amount of uninhibited enzyme,
it can be deduced that the formation of the irreversiblv inhibited enzvme
proceeds with the velocity
_. 
-dlE"rJ 
, rn'=-fr=k.'udircJ [E"*J'
Integration of this differential equation yields
[E"11, = [Eu1,]o exp (-k-, tt l$K t).
When the residual activity ([Euk1]/[Eukt]0) after the incubation time t is
plotted on semilogarithmic paper against the incubation time, a straight line
is obtained. The slope ofthis line gives the apparent reaction constant (kuoo)
of the inactivation process. In formula:
tilKapp = _K*: 
nf .r K
The values of k*2 and Kt can be obtained in the usual way by plotting
l/kuoo against l/[I]. An example of this approach is given in figures I and
The inhibitors used in this study were first described by Myers and
co-workers [26,27] who tested their inhibitory activity towards acetylcho-
line esterases; their chemical structure is given in table IL Table II summa-
rizes the results of a first screening of the inhibitory activity of the tested
compounds towards the factors IIu, VII., IX" and Xu. The k3s values given in
table II were calculated af,ter a fixed constant time interval (30 min) without
a control of the actual time course of the inactivation and, therefore, must
be considered as a rough estimation of the inhibitory capacity of the com-
pounds under consideration.
The compounds that seemed to be good and/or specific inhibitors dur-
ing this first screening were tested again with the factors IIu, VII', IXu, and
Xu, but this time the inhibitor concentration was the same with all four
coagulation factors. The purity of the compounds used for this second
screening was also checked by NMR spectroscopy. All compounds except
compounds No. 13, 16, and 35 had a purity of at least 97 o/o; the compounds
No. 13, 16, and 35 seemed to be partially degraded. The results of this
second screening are shown in italics in table II.
In order to facilitate the evaluation of the inhibitory capacity of the
compounds tested, the kuoo values for the inhibition of the coagulation fac-
tors with diisopropylfluorophosphate (DFP) are given in table III.
5 Z l
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zo
16.0
19.8
0.4
0.2
0.4
J J
2.9
33.0
0.7
0.2
0.4
< 6
0
< 2.9
1 . 7  0
0.2 0
0.4 0
0
0
0.4
0.6
5 - Z  U
0.5 0
44
0
o
t9 .8
0.4
0.6
6
9.0
0.6
0.6
0
< 2.9
2.5
0.5
o
5.9
2.5
0.5
5 . 1
0.5
4 - O
0.5
20
5.9
44
0
J
0
J . Z
0.5
1 . 6
0.5
2.8
0.5
20
9.0
0
0
0 0.4 44
0 0 . 2 0
0 1.0 20
0.8
0.2
1 .0
0.8
0.2
1 .0
t . 4
0.2
1.0
6
t2
0
0
0
1 6
0.3
0.4
0.2
t 2
1 .9
1 .9
0.6
0.4
0.2
0.6
0.4
0.2
3 0 . 3 3
2.8 0.4 0
0 0 . 2 0
t 2
12
12
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Tabteil (eont.)
No.'8hetd@l.skucture sfthc'i8Bflbitor
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c l o
$9-8-*'-"'
5 1 .
t l
-c-NH-CH3
52. To, o A
*oo. -fl \o-3-t 111 Tris-Hct burrer\J \'\
53. fi'\? /\/
Ct-C-N.  
1  
a tc .Tr i3  buFfer  4Yo
+ The'in vitro inMbirory activity of the (Rh - O - P --+ S type compo'unds is mainly due to the (R):
- S - p -+ O isomers, which are present as an impurity in the preparations in eq,uilibrium with the
former compounds.
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Inhibition of Activated Clotting Factors
II" inhibition VII. inhibition IX" inhibition X^ inhibition
tIF kro IIF kro try kro tIF kro
mmoVl lO-a min-r mmoVl 10-a min-r mmoVl l0-a min-t mmoVl 10-a min-t
J J I
0.2
0.2
9
9.0
0.2
0.2
0.2
0.2
0.2
0.2
6
t2
0
0
0
0
0.2
0.2
0.2
0.2
0.2 l0
0.2 12
4.3 128
0.2 0
4.3 6
0.2 0
0.6
0.2
0.2 0
0.2 0
n t
0.2
0.2
0.2
0.8
0.5
0.8
0.5
0.5
0.5
< 3
< 2.8
< 3
<2.8
0.2 0
0.2 0
<20
19.8
< 6
2.9
< 6
2.9
1 A
0.2
>  128
J J . Z
r05
19.8
2.4
0.2
0.5
0.5
22
22.2
l2
I  1 . 7
20
19.8
77
28
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Table III. Inhibition of the coagulation factors IIu, VII., IXu, and X" by DFP
Coagulation factor [DFP] mmol/l
338
kuoo 10-a min-r
II"
VII"
IX"
xu
0.2
6.9
4.2
50
3,600
60
300
As judged from table II, there seem to occur rather specific inhibitors
for the different coagulation factors among the organic compounds tested.
The inhibitors that gave k3e values of 50 X l0-a min-r in these screenings
were used further to determine the krz and K values of the inactivation
processes (see below). As the data on the ineffective inhibitors gave infor-
mation on the active site as well, we did not omit the negative results.
Tables IV-VI give the kinetic constants of the interaction of the fac-
tors IIu, VIIa, and Xu, respectively, with their more or less specific inhibi-
tors. For the determination of the k*2 and lli values given in these tables,
samples were taken from the incubation mixture at different times and the
residual activity was measured. k*2 and K values were calculated as
described above. By sampling from the incubation mixture and dilution
with the substrate, the velocity of the inhibition reaction decreases and
competition between the inhibitor and natural substrate occurs. Because of
this dilution, and because the clotting times are short compared to the incu-
bation times, it can be assumed that the inactivation reaction does not
proceed further during the clotting test. For the same reasons' the inhibition
of thromboplastin and of the coagulation factors in the reagent by the inhib-
itor during the activity determination can be neglected.
As can be deduced from table II, among the rather specific irreversible
thrombin inhibitors, compounds No. 7 and 19 are the most promising.
Furthermore, it can be seen in this table that compound No. 3l inhibits
preferentially factor vIIu and compound No. I inhibits preferentially fac-
tor Xu. Compound No. l7 inhibits strongly all three factors, thrombin, VIIa
and X". of course, it should be kept in mind that table II shows the results of
a rough first screening and gives no real kinetic constants.
When comparing the tables IV, V, and VI, it is striking that the 'spe-
cific' inhibitors all belong to the class of the organic phosphorus com-
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inhibitors except com-pounds. Moreover, all the irreversible thrombin
pound No. 30 have the structure:
o _
l - \  |  / \Rr{  >0-  ?-0-(  ) -Rr
d 2
while compound No. 30 has the structure:
*.1\o- l -o-4\0,' \:./ | \:/
R2
As can be seen in the general scheme for the reaction of serine proteases
with irreversible inhibitors given above, the inhibitor ltrst forms a revers-
ible complex with the enzyme [E ' I] which is further converted into an
irreversible complex [Einniui,"o]. K1 reflects the affinity of the enzyme for the
substrate, and kz is the reaction velocity of the irreversible step- As can be
seen in table IV, the compounds with a
G"'G"'-
group in the R2 position give relatively large k2 values; the smallest K1
values are found with the compounds which do not have aromatic groups in
the R2 portion.
From the results presented above it is clear that also small synthetic
compounds can discriminate between the closely related compounds
thrombin, factor VII. and factor Xu. The same conclusion was reached by
other groups. Okamoto et al. [30] studied a series of thrombin inhibitors
belonging to No-naphtalenesulfonyl-I-argine derivates. The structure of
these inhibitors is characterized by three entities: a positively charged group
(the amino acid argine), an aromatic group (the dansyl group, attached to
the cr-NHz group of arginine), and a hydrophobic carbon chain (attached to
the carboxyl group of arginine; optimal chain length 3 or 4 C-atoms). These
authors reported I5s values for these compounds in the range from 0.03 to
2 pmol/l when frbrinogen (3 pmol/l) or N"-benzoyl-Z-phenylalanyl-l-valyl-
I-aryinine-p-nitroanilide (100 pmol/l) is used as a substrate. These values
are of the same order of magnitude as the K1 values described in this article.
Kettner and Shaw [16] reported inactivation experiments of thrombin by
tetra- and tripeptide argine chloromethyl ketones. The peptide part of these
substrates contains the amino acid sequence at the site cleaved by thrombin
in its physiological substrates. The compounds Val-Pro-Arg-CHzCl (analog
of the factor XIII cleavage site) and Ile-Pro-Arg-CHrCl (analog of the pro-
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Table IV. Specific inhibition of factor IIu
No. Chemical structure of the inhibitor
o
I
a-ll
\./
340
4 0
n,o,-so-{-o$*0,
.,e!-"-+-o-S.,
8 ' l \ ?z - .
Noz{ )-o-?-o< )-Noz
W I W
NH
I
cHg
l-\ + ,t\Noz-( )-?-o< )-r,ro,
17 .
QHzl -
r-\4
1 8 .  It-\ t l-\Noz{  }o-?-o{  } ,u0,
CHc
t -
cHg
*o,{}o-$-o{}*o,' \-/ r \:,/
/ cHr
cH3 cH3
19 .
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Inhibitor
concentration
mmol/l
Enzyme
concentralion
l0-3 mmol/ l
kupp
l0 -2  m in - l
k2
l 0 -2  m in - r
Ki
l0-s mol/ l
1 .30
1.04
0.65
0.26
2.60
z-oz
1  1 1
t . 7 7
203 . 11 . 6
5.32.5
342.8
0.20
0 .  l 6
0.  l0
0.04
2 .21
r .80
1 . 6 5
l . l 6
1  1 ^t . z +
0.99
0.62
0.25
l - l 2.36
t .97
1.30
1 .25
3.68
3 .  l 0
2.39
0.47
0.28
0 .  t 4
l 5
0.56
0.39
0.28
2 3 . 1
28.9
I  1 . 6
2225
0.33
0.33
0.20
0 .  l 0
3.03
3.47
1.62
2 . t 7
7.9
r00| .'72.OO
1.60
1.00
0.40
2 .41
1.40
t .23
1.04
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Tabb fV. (cont.)
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No. Chemical structure of the inhibitor
20.
cHr-  cH?
t ' t -
CHa CHr
. i  / -
cHz
2t' 
,o,-So-!-o$ro,-\-/ 0
cH3cH2ooc{\!.- l - 
"{} coocH 2cH3
30.
0
I
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Table V, Specific inhibition of factor VII.
No. Chemical structure of the inhibitor
3 1 t
cH3cH2ooc - cH- 5- P- OCH3
cH3cH2ooc-cH2 ?
cHg
lnhibition of Activated Clotting Factors
Inhibitor Enzyme kupp kz K
concentration Concentration l0-2 min-r l0-2 min-t l0-5 mol/l
mmoVl 10-3 mmoVl
343
1.63 2.3 2.29
1 . 3  l  2 . t 3
0.82 2.64
0.33 2.00
2.5
0.39 2.3 6.71 l  l
0 .31  6 .12
0.  r  9  5.20
0.08 2.65
25
0.44 2.3 2.05
0.35 1.96
0.22 1.73
0 .09  l .  16
102.5
Inhibitor Enzyme kapp k2 K
concentration concentration l0-2 min-r l0-2 min-r l0-5 mol/l
mmol/l l0-r mmol/l
r . l r  3 . 6
0.89
0.5 5
0.22
3.30 calculation impossible
3 .  1 5
3.78
9.04
22.8
18 .2
18.2
l t .4
4.6
9.2
13 .9
16.0
t t .2
J . l
2,500253.6
v.d. Woerd-de Lange/van Dam-Mieras/Hemker
Table VI. Specific inhibition of factor Xu
344
t 0
- '  I
F -  P_  NH
I
NH
1 7 .
l-\
N0,-{ 'F
g
{Aro,
o
+
o - P - o
cr-r,
t -
/\
l t l
v
thrombin cleavage site) inactiYate thrombin by 500/o in less than 25 min at a
concentration of 7.5 X I 0-8 M. The compound Gly-Val-Arg-CH2Cl [analog
ofthe cleavage site in the fibrinogen A (o) chainl was effective at a concen-
tration of 2 X 10-6 moVl. The authors reported that the compounds with
the proline residue in the P2 composition were markedly more reactive with
thrombin than with plasma kallikrein, plasmin, urokinase, and factor Xo.
Markwardt [25] described irreversible thrombin inhibitors derived from the
competitive inhibitors benzylamine and benzamidine by introduction of a
reactive fluorosulfonyl moiety at the aromatic ring. These compounds, ami-
nomethyl and amidinofluorosulfonylbenzenes, possessed an inhibitory ef-
fect towards thrombin that surpassed that of DFP and phenylmethyl sulfo-
nylfluoride (PMSD.
No. Chemical structure of the inhibitor
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